Tau hyperphosphorylation induces oligomeric insulin accumulation and insulin resistance in neurons
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Insulin signalling deficiencies and insulin resistance have been directly linked to the progression of neurodegenerative disorders like Alzheimer's disease. However, to date little is known about the underlying molecular mechanisms or insulin state and distribution in the brain under pathological conditions. Here, we report that insulin is accumulated and retained as oligomers in hyperphosphorylated tau-bearing neurons in Alzheimer's disease and in several of the most prevalent human tauopathies. The intraneuronal accumulation of insulin is directly dependent on tau hyperphosphorylation, and follows the tauopathy progression. Furthermore, cells accumulating insulin show signs of insulin resistance and decreased insulin receptor levels. These results suggest that insulin retention in hyperphosphorylated tau-bearing neurons is a causative factor for the insulin resistance observed in tauopathies, and describe a novel neuropathological concept with important therapeutic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Gustafsson, M. G. L. (2000) · Journal of Microscopy · doi:10.1046/j.1365-2818.2000.00710.x · Cited by 3,786
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158
Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L.-L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.030 · Cited by 1,118
O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease
Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., & Gong, C.-X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400348101 · Cited by 775
Rivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723 · cited 1×
“, 2010) and post-mortem analysis of Alzheimer’s disease brains has shown downregulated insulin and insulin receptor mRNA levels, together with insulin and insulin receptor substrate 1 (IRS1) signalling impairments (Rivera et al., 2005; Talbot et al., 2012).”
BackgroundEvolution of the neuropathology of Alzheimer's disease
Braak, H., & Braak, E. (1996) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1996.tb05866.x · Cited by 710 · cited 2×
“These areas were selected according to the progression of tau pathology in Alzheimer’s disease, which initiates in the entorhinal cortex, continues in the hippocampus and reaches neocortical regions in the most advanced stages of the disease (Braak and Braak, 1996).”
Background
Cited by
Insulin and Insulin Resistance in Alzheimer’s Disease
Sędzikowska, A., & Szablewski, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189987 · Cited by 377
Alzheimer's disease and type 2 diabetes: a critical assessment of the shared pathological traits
Chatterjee, S., & Mudher, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00383 · Cited by 270
Role of the Blood-Brain Barrier in Central Nervous System Insulin Resistance
Rhea, E. M., & Banks, W. A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00521 · Cited by 263
Effect of nutrition on neurodegenerative diseases. A systematic review
Bianchi, V. E., Herrera, P. F., & Laura, R. (2021) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1681088 · Cited by 249
“In patients with metabolic syndrome, PET neuroimaging investigation showed an accelerated β-amyloid deposition in the brain [203].”
BackgroundKapogiannis, D., Mustapic, M., Shardell, M. D., Berkowitz, S. T., Diehl, T. C., Spangler, R. D., Tran, J., Lazaropoulos, M. P., Chawla, S., Gulyani, S., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2462 · Cited by 241
Targeting the Synapse in Alzheimer’s Disease
Jackson, J., Jambrina, E., Li, J., Marston, H., Menzies, F., Phillips, K., & Gilmour, G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00735 · Cited by 215
“Insulin accumulations track the progression of tau pathology in these tissues, suggesting potential for a mechanistic relationship between these species (Rodriguez-Rodriguez et al., 2017).”
BackgroundPeng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110
Li, H., Liu, C.-C., Zheng, H., & Huang, T. Y. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0139-3 · Cited by 103
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Iron Deposition Leads to Hyperphosphorylation of Tau and Disruption of Insulin Signaling
Wan, W., Cao, L., Kalionis, B., Murthi, P., Xia, S., & Guan, Y. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00607 · Cited by 84
“Furthermore, investigations also reveal that insulin resistance in neurons promotes the phosphorylation level of tau (36–38), and in turn hyperphosphorylation of tau also causes dysfunctional insulin signaling (39, 40).”
BackgroundHippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies
De Bastiani, M. A., Bellaver, B., Brum, W. S., Souza, D. G., Ferreira, P. C. L., Rocha, A. S., Povala, G., Ferrari-Souza, J. P., Benedet, A. L., Ashton, N. J., et al. (2023) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2023.03.001 · Cited by 57
Metadata
- Authors
- Rodriguez-Rodriguez, P., Sandebring-Matton, A., Merino-Serrais, P., Parrado-Fernandez, C., Rabano, A., Winblad, B., Ávila, J., Ferrer, I., & Cedazo-Minguez, A.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-10-13
- Volume
- 140
- Issue
- 12
- Pages
- 3269-3285
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2761422368
- Cited by
- 94
- References
- 17
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.